KNOXVILLE, TN, April 16, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today said that data from its clinical trial of autolytic cancer immunotherapy PV-10 (rose bengal disodium) as a single-agent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback